Table 2.
Multivariate analysis of transplant outcomes in intermediate-risk AML adults with FLT3-wt in CR1 MRD negative.
| RI | NRM | LFS | OS | |||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| HAPLO vs ASCT | 0.4 (0.27–0.6) | <0.0001 | 7.02 (3.26–15.08) | <0.0001 | 0.86 (0.62–1.2) | 0.37 | 1.69 (1.09–2.61) | 0.018 |
| Age (per 10 years) | 1.12 (0.99–1.26) | 0.067 | 1.89 (1.43–2.49) | <0.0001 | 1.25 (1.12–1.39) | <0.0001 | 1.61 (1.38–1.87) | <0.0001 |
| Year of HSCT | 1 (0.95–1.06) | 0.94 | 0.93 (0.84–1.03) | 0.15 | 0.99 (0.95–1.04) | 0.69 | 0.94 (0.88–1) | 0.04 |
| Female vs male | 1.02 (0.76–1.37) | 0.89 | 1.18 (0.69–1.99) | 0.55 | 1.05 (0.81–1.36) | 0.71 | 1.38 (1–1.9) | 0.052 |
| Time diagnosis to HSCT (mo) | 0.99 (0.95–1.04) | 0.79 | 1.01 (0.96–1.06) | 0.64 | 1.01 (0.98–1.04) | 0.59 | 1.01 (0.98–1.05) | 0.51 |
| NPM1 mut vs wt | 0.43 (0.3–0.6) | <0.0001 | 0.94 (0.48–1.82) | 0.85 | 0.5 (0.37–0.68) | <0.0001 | 0.44 (0.29–0.66) | <0.0001 |
| China vs other countries | 0.55 (0.31–0.98) | 0.043 | 1.48 (0.4–5.52) | 0.56 | 0.63 (0.36–1.1) | 0.1 | 0.89 (0.34–2.3) | 0.8 |
HR hazard ratio, CI confidential interval, HAPLO haploidentical stem cell transplantation, ASCT autologous stem cell transplantation, HSCT hematopoietic stem cell transplantation, mo months, mut mutation, wt wild-type.